Furthermore, taking into account that (1) EGF triggers NF-κB activation [37–39] and (2) EGFR/NF-κB pathway crosstalk is known to promote resistance to anti-cancer therapies [40–43], a similar pathway-focused analysis was performed to establish the effects of Pan-HER on the NF-κB pathway (Additional file Tables: Supplemental Table S5). Here, EGF is linked to cancer.